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Abstract
Amyotrophic lateral sclerosis (ALS) is a degenerative motor neuron disease which currently has no cure. Research using rodent ALS models
transgenic for mutant superoxide dismutase 1 (SOD1) has implicated that glial–neuronal interactions play a major role in the destruction of
motor neurons, but the generality of this mechanism is not clear as SOD1 mutations only account for less than 2% of all ALS cases. Recently,
this hypothesis was backed up by observation of similar effects using astrocytes derived from post-mortem spinal cord tissue of ALS patients
which did not carry SOD1 mutations. However, such necropsy samples may not be easy to obtain and may not always yield viable cell cultures.
Here, we have analysed olfactory mucosa (OM) cells, which can be easily isolated from living ALS patients. Disease-specific changes observed
when ALS OM cells were co-cultured with human spinal cord neurons included decreased neuronal viability, aberrant neuronal morphology and
altered glial inflammatory responses. Our results show the potential of OM cells as new cell models for ALS.
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Introduction
Amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, is a
neurodegenerative disorder of unknown origin characterized by pro-
gressive degeneration of upper motor neurons in the motor cortex
and lower motor neurons in the brainstem and the spinal cord, initiat-
ing in mid-age life [1]. It results in muscle paralysis and ultimately
death because of respiratory failure, most commonly within 3–
5 years of diagnosis [2].
The classical division of ALS into familial or sporadic types has
been made depending on patient family history. Approximately, 90%
of ALS patients are considered sporadic (sALS) as they appear to
occur randomly throughout the community, whereas the remaining
10% are familial (fALS) cases [3], showing autosomal dominant
inheritance in the majority of instances. Of these, ~12% are associ-
ated with mutations in the Cu/Zn superoxide dismutase (SOD-1) gene
[4], which seem to confer toxic gain of an unknown function rather
than loss of normal SOD1 activity [5]. Other genes, including TARDBP
(TAR DNA-binding protein 43) [6], FUS (fused in sarcoma) [7, 8] and
angiogenin (ANG) [9] have also been implicated in fALS. Recently, a
large GGGGCC repeat expansion in the first intron of the C9orf72 gene
has been reported to be the most common genetic cause of ALS,
accounting for approximately 40% of fALS and 7% of sALS [10–12].
Sporadic and familial ALS cases are however, clinically indistinguish-
able, suggesting similar underlying pathophysiological mechanisms
of neurodegeneration.
While several pathogenic processes for the motor neuron degen-
eration observed in ALS have been proposed, one of the most
prevailing hypotheses supports a non-cell autonomous process:
neighbouring astrocytes are thought to play a major role in disease
progression [13–18]. Nevertheless, the basis for the specificity of
astrocytes and other glial cells in the selective degeneration of
motor neurons remains unclear. Indeed, the molecular mechanisms
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underlying neuronal death in ALS are presently not fully determined
and appear to be multifactorial. Glutamate excitotoxicity, mitochon-
drial dysfunction [19], accumulation of intracellular protein aggre-
gates [20], oxidative stress [21], hypoxia [22, 23], alterations in
RNA metabolism [24], impaired axonal transport [25], growth factor
deficiency [26] and neuroinflammation [27] have all been proposed
to be involved.
Evidence of inflammation is observed in post-mortem tissue
[28–31], in cerebrospinal fluid [32, 33] and in blood samples [34]
from fALS and sALS patients. These observations are in agreement
with previous observations of neuroinflammation in rodent models of
ALS [35, 36]. In transgenic mice expressing mutant SOD-1, increased
levels of toll-like receptors (TLRs) are detected [37]. Microglial neuro-
toxic inflammatory responses have been suggested to be facilitated
via TLR2 [38]. In addition, it has been shown that mutant SOD-1
binds to CD14, which is a co-receptor of TLR2 and TLR4, and that the
microglial activation mediated by mutant SOD-1 can be attenuated
using TLR2, TLR4 and CD14 blocking antibodies [39]. In accordance,
Casula et al. have reported an up-regulation of TLR2 and TLR4 as well
as other pro-inflammatory molecules such as Receptor for Advanced
Glycation End products and High Mobility Group protein B1 in reactive
glia in the spinal cord of sALS victims [30]. One unanswered question,
however, is whether these correlative observations reflect a causal
relationship, with inflammatory activation provoking ALS, or alterna-
tively, ALS pathology triggering inflammatory responses.
A large amount of ALS research has made use of in vitro and
in vivo models based on overexpression of genes with mutations
linked to familial ALS. However, as 90% of ALS cases are sporadic, it
is difficult to ascertain how representative these models are with
respect to the human disease. This highlights one of the main obsta-
cles currently limiting the study also of other neurological diseases:
the need for patient-derived cell models that are relevant and robust
enough to produce the large quantities of cells required for molecular
and functional analyses. Current efforts on developing sALS models
have used patient-derived samples from post-mortem brain, spinal
cord and muscle [28, 40]. More recently, sALS patient-derived cell
cultures have been developed including astrocytes differentiated from
neural progenitor cells obtained from spinal cord necropsies [41], and
induced pluripotent stem cells [42, 43]. All these models represent
various degrees of compromise between relevance for understanding
disease aetiology and suitability for diagnostics and drug discovery.
In this study, we have explored an alternative patient-derived neu-
ral model for the study of sALS disease: primary olfactory mucosa
(OM) cultures derived from sporadic ALS patients. The OM is easily
accessible for non-invasive biopsy in human adults [44]. Either biop-
sied tissue or derived primary cultures have been shown to exhibit
alterations in Rett’s syndrome, Alzheimer’s disease, fragile X syn-
drome, schizophrenia, Parkinson’s disease and bipolar disorder with
respect to healthy donors [45–50]. OM-derived primary cultures con-
tain several types of extraepithelial cells including multipotent stem
cells [51–54] as well as olfactory ensheathing glia [55] which nor-
mally support the growth of primary olfactory axons from the neu-
roepithelium in the nasal cavity to the brain [56]. These glia are
present both in the peripheral as well as the central nervous system,
and share characteristics of both astrocytes as well as Schwann cells.
Moreover, OM-derived ensheathing glia have been used for therapeu-
tic purposes in spinal cord injury [57, 58] and even in ALS [59–61].
The fact that OM transplants exhibit regenerative capacity in spinal
cord [58], led us to speculate that the interaction of OM-derived cells
with spinal cord-derived motor neurons may recapitulate the non-cell
autonomous properties described for ALS.
It is conceivable that olfactory ensheathing cells (OECs) may
share some similar characteristics of inflammatory cells, providing a
degree of immunological protection against infections in the olfactory
system. Indeed, microarray analysis has revealed that, relative to as-
trocytes and Schwann cells, OECs express higher levels of a number
of innate immune factors, including lysozymes, chemokines and
monocyte chemotactic proteins, suggestive of functions in modulat-
ing neuroinflammation [62]. OECs have also been demonstrated to
express TLRs and possess the cellular machinery to respond to cer-
tain bacterial ligands [63, 64].
Another interesting aspect of using OM cells to model ALS is that
it has been proposed that chemosensory impairment is an early
symptom of many neurodegenerative diseases [65, 66], including
ALS [67, 68]. The mucus covering olfactory epithelium has been
shown to contain reduced levels of growth factors that may be related
to this reduction in olfactory capacity [68]. Thus, this olfactory dys-
function suggests that mucosa neuroepithelium components might
also be affected in neurodegenerative disorders, supporting their use
as disease models. Notably, disease-specific alterations in gene
expression, protein expression and cell function have previously been
found in primary OM cultures derived from patients with schizophre-
nia and Parkinson’s disease [69] as well as spastic paraplegia [70].
In this study, we propose the use of OM to model ALS, demon-
strating their negative effect over motor neuron survival and morphol-
ogy as well as the activation of inflammatory responses as a
consequence of this deleterious interaction.
Materials and methods
Reagents and antibodies
All media such as Hank’s balanced salt solution (HBSS), HBSS supple-
mented with Ca2+ and Mg2+, DMEM, DMEM:F12 and Neurobasal med-
ium as well as other cell culture reagents including L-Glutamine,
TrypLE, bovine pituitary extract, B-27 supplement, N-2 supplement were
purchased from Gibco, Life Technologies (Barcelona, Spain).
Other special reagents used were: trypsin, penicillin, streptomycin,
bovine serum albumin, trypan blue, retinoic acid and lipopolysaccharide
(LPS), all purchased from Sigma-Aldrich (St. Louis, MO, USA); DNase-I
(Roche, Mannheim, Germany); foetal calf serum (FCS, Hyclone, Logan,
UT, USA); forskolin (Alomone, Jerusalem, Israel); primocin (InvivoGen,
San Diego, CA, USA); carboxyfluoresceinsuccinimidyl ester (CFSE,
Molecular Probes/Life Technologies, Eugene, OR, USA); brain-derived
neurotrophic factor (BDNF, Santa Cruz Biotechnology, Santa Cruz, CA,
USA), forskolin (Alomone Labs, Jerusalem, Israel); Smoothened agonist
(SAG, Merck/Calbiochem, Darmstadt, Germany); Fluoromount-G (South-
ern Biotech, Birmingham, AL, USA); matrigel (BD Biosciences/Pharmin-
gen, Madrid, Spain) and DAPI (Calbiochem, Nottingham, UK).
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The antibodies against the following proteins were used: bIII-tubulin
[71]; S100b, SOD-1 and GAPDH (from Sigma-Aldrich); GFAP and nestin
(from Chemicon, Temecula, CA, USA, now part of Merk-Millipore,
Darmstadt, Germany); vimentin (Boehringer, Ingelheim, Germany); p75
and neuroligin (from Santa Cruz Biotechonology). The secondary anti-
bodies used were anti-rabbit, antimouse and anti-goat Alexa 555, and
Alexa 488 (Molecular Probes/Life Technologies) for immunofluores-
cence and peroxidase-labelled secondary antibodies (Sigma-Aldrich) for
Western blot.
Culture of patient-derived OM
Human OM primary cultures were obtained and cultured as previously
described [72]. OM primary cultures were derived from human nasal
endoscopic biopsies that were carried out by otolaryngologists (E. Scola
and J. Medina) at the Gregorio Mara~non Hospital, Madrid. Written
informed consent was obtained from all healthy or ALS patients, and
the study was approved by the Gregorio Mara~non Hospital ethics com-
mittee. Pre- and post-nasal biopsy olfaction was evaluated in ALS
patients and controls, according to the Barcelona Smell Test-24 (BAST-
24), previously validated for the Spanish population [73]. No significant
changes were found between the ALS patient group and controls, either
before or after nasal biopsy. Briefly, tissue samples were kept at 4°C in
HBSS until processing by disaggregation with 0.05% trypsin in HBSS
for 20 min, inactivation with one volume of FCS, followed by a 5 min.
treatment with 0.01% DNAse-1 in HBSS supplemented with Ca2+ and
Mg2+, after which the cell pellet was finally resuspended in ME medium:
DMEM:F12 (1:1), 10% FCS, 2 mM glutamine, 20 lg/ml bovine pituitary
extract, 2 lM forskolin, 50 lg/ml primocin. Unless specified, OM cells
were grown as adherent monolayer cultures in ME medium.
Immunofluorescence assay
Immunofluorescence analysis was performed as previously described
[68] using the primary and secondary antibodies detailed above and fol-
lowed by 10 min. incubation with DAPI (1/500). Coverslips were
mounted with Fluoromount-G according to the provider’s guidelines.
Representative images were taken with an Axiovert200 (Zeiss, Oberko-
chen, Germany) inverted microscope coupled to a CCD camera using
Metavue 5.07 software (Universal Imaging, Bedford Hills, NY, USA).
Neuronal survival assay
Preparation of frozen stocks of differentiated neurons from human foe-
tal spinal cord neural precursors was as previously described [76]. For
co-cultures with patient-derived glia, OM samples were first seeded in
six-well plates (105 cells per well). After 24 hrs, differentiated neurons
were thawed out and labelled with 25 lM CFSE in PBS containing 1%
bovine serum albumin, for 15 min. at 37°C. After labelling, cells were
diluted with 5 ml of neuronal medium [DMEM:F12 supplemented with
B-27 (20 ll/ml), N-2 (10 ll/ml), streptomycin (100 U/ml) and penicillin
(100 lg/ml)]. The cells were then centrifuged and resuspended in 3 ml
of neuronal medium at 37°C. The percentage of live neurons was deter-
mined by trypan blue exclusion and the labelled cells were seeded in
neuronal medium over OM monolayers at a neuron:OM ratio of 1:6. Cul-
ture medium was changed partially three times per week. After 2 weeks
of co-culture cells were detached with TrypLE, washed with PBS and
resuspended in 200 ll PBS for flow cytometry analysis. The total num-
ber of CFSE-positive cells was counted in 110 ll of each sample using
a FACS CantoII flow cytometer (Becton Dickinson Biosciences, San
Jose, CA, USA) and the results analysed using FlowJo software (Tree-
Star Inc., Ashland, OR, USA).
Olfactory mucosa survival assay
Olfactory mucosa cells were seeded in six-well plates (105 cells/well).
After 24 hrs, ME culture medium was substituted for neuronal medium
(DMEM:F12 supplemented with 20 ll/ml B-27, 10 ll/ml N-2, 100 U/ml
streptomycin and 100 lg/ml penicillin) after which the medium was
renewed partially three times per week. Twenty-three days after seeding,
cells were collected and the total number of surviving cells was counted
in a FACS CantoII flow cytometer (Becton Dickinson Biosciences) and
the results analysed using FlowJo software (TreeStar Inc.).
Neuronal morphology assay
Differentiation of human foetal spinal cord neural precursors along the
motor neuron lineage was carried out by culturing them in Neurobasal
medium supplemented with N-2 (5 ll/ml), BDNF (50 ng/ml), retinoic
acid (100 nM), Forskolin (5 lM) and streptomycin/penicillin (100 U/ml
and 100 lg/ml, respectively) during the first 4 days and Neurobasal
medium similarly supplemented with N-2, BDNF, retinoic acid, strepto-
mycin/penicillin, and SAG (100 nM) for up to 3 weeks.
A subconfluent culture of OM cells was grown on round coverslips
in 24 multi-well plates and differentiated neurons were seeded on top
(5 9 103 neurons per well) in Neurobasal medium supplemented with
N-2 (5 ll/ml) and streptomycin/penicillin (100 U/ml and 100 lg/ml,
respectively). The medium was changed partially three times per week.
After 2 weeks of co-culture, cells were fixed with paraformaldehyde and
immunofluorescence analysis was performed as previously described
[75] using 195 antiserum specific for bIII-tubulin [71] diluted 1:3000
during 1 hr followed by incubation with anti-rabbit Alexa 555 and DAPI.
Representative images were taken and morphological quantification was
performed by scoring a minimum of 15 bIII-tubulin-positive cells in at
least nine random fields per condition into different morphologies:neu-
ronal, when the cells exhibited filamentous bIII-tubulin staining and the
length of the longest neurite was at least four times that of the longest
axis of the nucleus; non-neuronal, when the bIII-tubulin stain was dif-
fuse, cytoplasm was more expanded and its longer part was smaller
than four times the size of longest axis of its corresponding nucleus.
Cells not matching either morphology were discarded from the analysis.
Lentivector production and titration
The viral vectors used to express wild-type and mutant SOD-1 were
LentiSOD1wt and LentiSOD1G37R [18]. The inflammation-responsive
lentivectors LV-NFjBp-luc, LV-ESELECp-luc, LV-IL1-IL6p-luc encode the
luciferase-IRES-GFP reporter construct under the control of 69 NFjB,
E-selectin and IL1-IL6 hybrid promoters, respectively; the LV-SFFVp-luc
lentivector encodes the same reporter under the control of the SFFV
constitutive promoter [74]. Lentiviral stocks were produced as previ-
ously described [75]. Vector titre was determined in OM cells by
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infection with serial dilutions of the viral supernatants and the number
of transduced cells determined 48 hrs post-infection by flow cytometry
(FACSCalibur, BD Biosciences) using GFP expression.
fALS cell model
The foetal human primary astrocyte cell line, HA1800, was obtained
from ScienCell Research Laboratories (Carlsbad, CA, USA) and was cul-
tured according to the provider’s instructions. These cells were infected
with LentiSOD1wt and LentiSOD1G37R [18] before each experiment.
Innate immune response assay
Astrocytes and OM cells were infected with the indicated lentivectors
2 days after the treatment under study. For LPS stimulation, 24 hrs
before treatment, cells were subjected to serum starvation by incubation
overnight in DMEM containing 2% FCS to minimize interference by
serum-borne factors. Cells were then cultured in the presence of LPS
(500 ng/ml) in DMEM containing 2% FCS for the indicated period.
For co-culture, subconfluent spinal cord neural precursors were
seeded in 96 multi-well plates coated with matrigel and differentiated
along the motor neuron lineage by culture in Neurobasal medium sup-
plemented with N-2 (5 ll/ml), BDNF (50 ng/ml), retinoic acid (100 nM),
Forskolin (5 lM) and streptomycin/penicillin (100 U/ml and 100 lg/ml,
respectively) during first 4 days and Neurobasal medium similarly sup-
plemented with N-2, BDNF, retinoic acid, streptomycin/penicillin, and
SAG (100 nM) during the last 5 days. Thereafter, OM cells and human
astrocytes expressing SOD-1 (where indicated) and harbouring lucifer-
ase reporter constructs, were seeded on top of the neurons at a density
of 7000 per well in Neurobasal medium supplemented with N-2 (5 ll/
ml) and penicillin/streptomycin (100 U/ml and 100 lg/ml, respectively).
Medium was changed every 2 days and luciferase assays were per-
formed at the time indicated for each experiment.
Luciferase assay
Cells were washed with PBS and frozen at 80°C. Luciferase activity
was measured with an AutoLumat LB953 luminometer (Berthold
Technologies, Bad Wildbad, Germany) using a commercially available
assay system (E1501; Promega, Madison, WI, USA) following the
manufacturer’s instructions. All treatments were performed in
triplicate. Normalized luciferase activity represented in the graphs was
the result of dividing the relative light unit (RLU) values obtained for
each inflammation-responsive vector by the mean RLU value obtained
for the constitutive SFFV promoter vector under the same conditions.
Western blot assay
Cells were collected, washed and resuspended in lysis buffer (50 mM
Tris-HCl pH 7.5; 300 mM NaCl; 0.5% sodium dodecyl sulphate and 1%
Triton X-100) and incubated for 15 min. at 95°C. Protein concentration
of the extracts was measured using the Dc protein assay kit (Bio-Rad,
Hercules, CA, USA) and 30 lg of each cell extract was resolved by elec-
trophoresis in 12% polyacrylamide gels in the presence of sodium
dodecyl sulphate. After electrophoresis, proteins were transferred to
nitrocellulose membranes which were blocked with 10% low-fat milk in
PBS-T (0.3% TWEEN 20 in PBS) and incubated overnight at 4°C with
specific primary antibody against SOD-1 (1:1000) and anti-GAPDH anti-
body (1:5000). After washing, membranes were incubated with peroxi-
dase-labelled secondary antibodies and the immunoreactive proteins
were visualized using the enhanced chemiluminescence detection kit
Western Lightning Plus-ECL (PerkinElmer, Waltham, MA, USA) following
the supplier’s instructions.
Statistical analysis
Statistical comparison of the data sets was performed with Student’s
t-test. The differences are given with their corresponding P-value, which
is the probability that the observed result could occur merely by chance
under the null hypothesis.
Results
Co-culture of neurons with ALS mucosa cells
diminishes their survival
As a result of the fact that the majority of ALS cases are not
associated with a known mutation [21], our first goal was to gen-
erate an ALS cell bank based on sporadic cases. Numerous stud-
ies have highlighted the relevance of glial cells in ALS
pathogenesis [13–18] and therefore we concentrated on OM as it
is a source of glia that can be obtained from living patients via a
small nasal endoscopic biopsy [72]. We generated a bank of OM
from eight healthy donors and seven ALS patients (Table 1). In
this study, we used culture conditions optimized to enrich for the
growth of glia cells [72]; we successfully obtained primary cul-
tures from all of the patients and did not detect any difference in
the efficiency, survival, growth rates, life span or antigenic mark-
ers in samples derived from ALS patients compared to those from
healthy donors (Figs S1 and S2, and Table 1). All cells were simi-
lar in their expression of the antigenic markers GFAP, vimentin,
S100b, neuroligin, nestin and the low affinity NGF receptor p75
(Fig. S2), all of which are characteristic of OECs. However, as a
cautionary note, our previous work has demonstrated that these
immunocytochemical properties do not clearly distinguish OECs
from other cell types such as fibroblasts or gliomas [72]. To test
whether these biopsy-derived glia exhibit disease-specific neurotox-
icity similar to that observed for spinal cord astrocytes derived
from ALS patient cadavers, we co-cultured them with differentiated
post-mitotic human spinal cord neurons [76] which we pre-
labelled with CFSE to facilitate quantification. The neurons were
plated over OM monolayers at a neuron:OM ratio of 1:6 (Fig. 1A)
and after 2 weeks of co-culture, cells were harvested and the total
number of surviving neurons was counted by flow cytometry. We
observed that neuronal survival was significantly higher when the
neurons were co-cultured with OM derived from healthy donors
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compared to when they were co-cultured with OM from ALS
patients (Fig. 1B).
Neuron morphology is aberrant in
co-cultures with OM from ALS patients
In addition to diminished survival when spinal cord neurons were
co-cultured with OM cells from ALS patients, we observed that the
morphology of the surviving cells was significantly affected (Fig. 2).
While neurons grown over control OM cells preserved their typical
morphology with a small cell body and long neuritis positive for
strong fibrillar bIII-tubulin staining (Fig. 2A, upper row), neurons
grown over OM cells from ALS patients often displayed aberrant
morphologies, exhibiting wider cell bodies and retracted neurites
with less fibrillar and more diffuse bIII-tubulin staining (Fig. 2A,
lower row). As OM cells may express low levels bIII-tubulin [72],
we optimized the bIII-tubulin staining sensitivity to exclusively label
CFSE-positive cells. For morphometric analysis, cells were scored
as neuronal if the length of the longest neurite was at least four
times that of the longest axis of the nucleus. Based on this crite-
rion, the data showed a significant reduction in the percentage of
cells with neuronal morphology when the neurons were co-cultured
with OM from ALS patients compared to when they were co-cul-
tured with OM from healthy donors. We thus concluded that co-
culture with OM derived from ALS patients not only reduced
neuronal survival but also modified the morphology of surviving
cells.






C1 Male 26 10 260
C2 Male 36 >10 364
C3 Female 51 >10 260
C16 Male 20 >10 260
C17 Female 25 >10 260
C18 Female 22 >10 260
C19 Male 29 >10 260
C20 Female 30 >10 364
ALS1 Male 57 >10 208
ALS3 Male 72 9 364
ALS4 Male 48 >10 208
ALS5 Male 36 10 208
ALS6 Female 61 >10 260
ALS7 Male 40 >10 364
ALS8 Male 39 >10 364
A
B
Fig. 1 Spinal cord neuron survival after
co-culture with olfactory mucosa (OM).
(A) Scheme of the procedure using flow
cytometry to study the survival of CFSE-
labelled spinal cord neurons after co-cul-
ture with OM cells from healthy control or
ALS donors. (B) Flow cytometry quantifi-
cation of the number of CFSE-labelled sur-
viving neurons after 2 weeks of co-culture
with OM cells or in the absence of these
cells (none). The left graph shows means
and standard errors of the mean (SEM) of
three independent assays of each OM
sample. Samples are ordered by ascend-
ing patient age within each group (control
and ALS). The right graph represents the
combined mean and SEM of the control
or ALS groups with the P-value for com-
parison of the means.
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Glial inflammatory response to LPS is
not altered in ALS
Mounting evidence suggests that neuroinflammation plays an
important role in the degeneration of motor neurons in ALS [77].
It has been demonstrated that reactive astrocytes and microglia
can release pro-inflammatory factors such as cytokines and
chemokines, which are harmful to neighbouring neurons [78]. To
test whether OM cells from ALS patients have an altered pro-
inflammatory state and/or a modified response to inflammatory
stimuli, we transduced OM cells with three different inflamma-
tion-regulated lentivector systems [74]. As a control, OM cells
were transduced with the same reporter cassette (luciferase-
IRES-GFP) under the control of a constitutively promoter
(SFFVp). We first transduced OM cells from healthy donors and
challenged them with a pro-inflammatory stimulus, LPS. We
observed efficient activation of the inflammation-regulated pro-
moters (NFjBp, IL1/IL6p and ESELp) after LPS treatment for 6
and 27 hrs (Fig. 3A). As the largest responses to LPS were
obtained with the NFjB and E-selectin promoters, we selected
these reporters for subsequent experiments.
Our next goal was to ascertain if abnormal pro-inflammatory
innate responses in ALS glia play a role in their toxicity to motor
neurons. For this, we used the inflammation-inducible expression
systems to first analyse human astrocytes overexpressing
SOD1G37R, a previously published genetic model of ALS; in this
model, the authors showed that co-culture with these modified
astrocytes was deleterious to mouse motor neurons [18]. We
thus compared astrocytes expressing either wild-type SOD1 or
the mutant SOD1G37R to control astrocytes (non-transduced) after
LPS treatment for 6 hrs (Fig. 3B and C). Luciferase activities
were lower in astrocytes than in OM cells, indicating less pro-
inflammatory response in this cell type. In addition, NFjBp and
ESELp reporter activity did not increase in astrocytes expressing
either wt SOD1 or mutant SOD1G37R; overall luciferase activity
was actually lower in transduced astrocytes compared to that
observed in control astrocytes. In the case of NFjBp, reporter
activity was significantly higher in the presence of mutant SOD1
than in the presence of wild-type SOD1. In addition, LPS chal-
lenge induced a significant increase in luciferase activity in pres-
ence of mutant SOD1, but not in the presence of wild-type
SOD1 (Fig. 3B). A similar effect was observed using the ESELp
A
B
Fig. 2Morphology of the surviving spinal
cord neurons after co-culture with olfac-
tory mucosa (OM). (A) Representative
immunofluorescence images of the surviv-
ing spinal cord neurons labelled for bIII-
tubulin after 2 weeks of co-culture over
monolayers of OM from four different
healthy control donors (upper row) and
four different ALS patients (lower row).
Nuclei were labelled with DAPI. (B) Mor-
phometric quantification of spinal cord
neurons after co-culture over OM cells.
CFSE-labelled cells were classified as:
neuronal if they exhibited filamentous bIII-
tubulin staining and the length of the lon-
gest neurite was at least four times the
length of the longest axis of the nucleus;
non-neuronal if they exhibited diffuse bIII-
tubulin staining and all neurites were
shorter than four times the length of the
longest axis of the nucleus. A minimum of
15 neurons in at least nine random fields
were scored for each OM sample. Graphs
represent the percentage of cells exhibit-
ing each morphology, showing means and
standard errors of the mean of eight dif-
ferent controls and seven different ALS
OM samples with the P-value for compari-
son of the means. The scale bar repre-
sents 50 lm.
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reporter although the differences were not statistically significant
(Fig. 3B).
We next used these inflammation-inducible reporter systems
to study the inflammatory response in OM cells from healthy
donors and ALS patients (Fig. 3D). Although we observed effi-
cient activation of both NFjBp (Fig. 3D) and ESELp (Fig. 3E)
reporters in response to LPS treatment, no significant differences
between ALS and healthy samples were observed, either in basal
conditions or after LPS exposure. Thus, our results indicate that
there is no alteration of the inflammatory response in OM cells
from ALS samples.
Olfactory mucosa from ALS patients shows
increased inflammatory response in
co-cultures with spinal cord neurons
We next posed the question if the altered inflammatory response
described for ALS might be a consequence, rather than the cause, of
the abnormal interaction between neurons and glia. To address this
issue, we co-cultured human astrocytes, either unmodified (control),
or overexpressing wild-type SOD1 or mutant SOD1G37R with differen-
tiated human spinal cord neurons (Fig. 4A and B). As we had
observed the largest response using the NFjBp reporter previously
(Fig. 3), we employed it to study the effects of only neuronal co-cul-
ture on the astrocytes (Fig. 4A). Under basal conditions (in the
absence of neurons), the SOD1-overexpressing astrocytes showed lit-
tle change in reporter activity compared to unmodified astrocytes;
neuronal co-culture significantly increased the luciferase activity in
astrocytes overexpressing wild-type SOD1, and this increase was
even greater in those overexpressing mutant SOD1G37R (Fig. 4A).
Western blot analysis confirmed similar levels of expression of wild-
type or mutant SOD1, ruling out the possibility that the different sen-
sitivities to the neurons were because of different SOD1 levels. These
results are consistent with the idea of the accumulation of wild-type
SOD1 in sporadic ALS patients [79] to adopt an abnormal pathogenic
conformation which may be exacerbated by overexpression or by cer-
tain point mutations.
We next applied the same methodology to measure the NFjB-
mediated response in OM samples derived from healthy donors and
ALS patients (Fig. 4C). Again, a significant increase in reporter activ-
ity was observed when the cells were co-cultured with spinal cord
neurons, with the OM cells from ALS patients showing higher lucifer-
ase activity than those from healthy donors (Fig. 4C). As increased
reporter activity in the ALS group is not observed in the absence of
co-culture with neurons, we conclude that the altered glial inflamma-
tory response in ALS is likely to be a consequence, rather than a
cause, of neuronal death, which may liberate inflammatory cytokines
which in turn activate NFjB-mediated responses.
Discussion
Multiple lines of evidence have shown the immune system, includ-
ing astrocytes and microglia, to be deleterious for motor neurons
in ALS. Reactive astrocytes and microglia may release pro-inflam-
matory factors such as cytokines and chemokines which are harm-
ful for the neighbouring cells [78]. However, their role as the
primary cause of the disease remains undetermined. Our data indi-
cate that there is no increased innate immune response of glia in
ALS: using the established model of SOD1 overexpression in
human astrocytes, we did not observe increased pro-inflammatory
response after LPS treatment and this result is similar when OM
cells from healthy donors and those from ALS patients are com-
pared. However, co-culture with motor neurons increases glial sen-
sitivity to pro-inflammatory stimuli in ALS: we observed augmented
NFjB-dependent reporter activity both in the SOD1-overexpressing
astrocyte model as well as in OM cells from ALS patients. These
results indicate that alterations in the innate immune response of
glia in ALS might be a consequence of their interaction with dam-
aged neurons rather than the cause of initial neuronal damage.
Nevertheless, once sensitized, the modified pro-inflammatory
response of glia in ALS could further worsen the state of neigh-
bouring neurons. In agreement with this concept, previous work
using a SOD1 transgenic mouse model demonstrated that microglia
and T cells initially slow disease progression, but at later stages
after accumulation of SOD1 protein, contribute to acceleration of
the disease [80]. Moreover, it has been shown in both ALS patients
as well as in mouse models that activation of microglia and astro-
cytes takes place only after distal axon degeneration [40].
Fig. 3 Study of the inflammatory response in ALS cell models. Cells were transduced with reporter lentivectors encoding the luciferase gene under
the control of three inflammation-responsive promoters (NFjBp, an artificial promoter containing multiple NF-jB binding sites; IL1/IL6p, consisting
of the human IL-6 promoter fused to the enhancer region of the human IL-1 promoter; or ESELp, the human E-selectin promoter) or the constitutive
spleen focus-forming virus promoter (SFFVp). Normalized luciferase activity was obtained by dividing the luciferase activity measured in relative light
units (RLU) for each inflammation-responsive promoter by the mean activity of the SFFVp reporter in the same conditions. Graphs represent means
and standard errors of the mean (SEM) of three independent samples. (A) Reporter activities in untreated control olfactory mucosa (OM) cells
(Basal) or after challenge with LPS (500 ng/ml) for either 6 or 27 hrs. (B) Reporter activities in control human astrocytes or those overexpressing
SOD1wt or SOD1G37R either without (Basal) or with LPS challenge for 6 hrs. Comparison of mean luciferase activities (corresponding P-values are
shown) after LPS treatment of astrocytes overexpressing SODG37R with those overexpressing SODwt revealed a significant increase using the NFjBp
reporter; this effect was similar using the ESELp reporter, although not statistically significant. (C) Western blot analysis of SOD1 expression in the
human astrocyte ALS cell models used in B. (D) The left graph shows luciferase activities of the NFjBp reporter in OM cells from eight control
donors and seven ALS patients either without (Basal) or with LPS challenge for 6 hrs. Samples are ordered by ascending patient age within each
group (control and ALS). The right graph represents the combined mean and SEM of the control or ALS groups. (E) Similar study to that shown in
D but using the ESELp reporter.
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The use of OM to model ALS offers certain advantages over other
cell models. The non-invasive and relatively simple nasal biopsy pro-
cedure provides a patient-derived source of living cells that can be
easily expanded to perform molecular analysis and functional assays.
Samples can be collected not only from patients showing genetic link-
age but also from sporadic cases which represent the majority of ALS
victims and are more difficult to model. Most importantly, in view that
sporadic ALS patients may show wide variability in disease aetiology
and responses to therapy, OM cells can be obtained from living
patients, offering the future possibility of personalized in vitro drug
screening prior to treatment of the patient. Presently, the majority of
patient-derived sALS models originate from post-mortem tissue
[28, 40, 41], placing limitations on the average cellular lifespan and
not offering any benefit to the donor. The advent of induced pluripo-
tent stem cells generated from sALS patients offers an expandable
cell model that can be obtained from living patients [42], but this
involves a complex, time-consuming and expensive protocol. On the
contrary, OM cell culture is a relatively simple and reproducible tech-
nique which can yield long-lived cultures without the need for genetic
manipulations which could generate undesired non-disease-related
alterations. Furthermore, OM cultures avoid the necessity for
inefficient, complex and expensive protocols to differentiate neural
precursors as they provide a direct source of neural cells, which, as
we have observed in the present study, recapitulate ALS-specific hall-
marks. Firstly, we observed that compared to healthy donor OM cells,
co-culture with those derived from ALS patients results in reduced
survival and aberrant morphology of spinal cord neurons, in agree-
ment with the deleterious effect of ALS glia on co-cultured neurons
previously reported [14–18]. This may be because of the generation
of a toxic factor and/or decreased trophic support by the glia [26].
The latter is particularly relevant in view of the fact that our controls
show that neurons exhibit drastically reduced survival in the absence
of mucosa cells (control samples ‘none’ in Fig. 1B and [72]). Sec-
ondly, we observed good correlation between the effects obtained
with OM cells from ALS patients and those from a previously pub-
lished ALS model using SOD1-expressing astrocytes [18]. While LPS
challenge did not result in increased NFjB-mediated response in ALS
samples, when OM cells or astrocytes were co-cultured with neurons,
an augmented sensitivity was observed in ALS samples that was not
detected in the absence of neurons. These data indicate that while
there may be no alteration of the innate immune response in cells
from ALS patients, the differential death of neurons after co-culture
A B
C
Fig. 4 Study of the inflammatory response in ALS cell models co-cultured with spinal cord neurons. Cells were transduced with reporter lentivectors
encoding the luciferase gene under the control of an artificial promoter containing multiple NF-jB binding sites (NFjBp) or the constitutive spleen
focus-forming virus promoter (SFFVp). Normalized luciferase activity was obtained by dividing the luciferase activity measured in relative light units
(RLU) for each inflammation-responsive promoter by the mean activity of the SFFVp reporter in the same conditions. Graphs represent means and
standard errors of the mean (SEM) of three independent samples. (A) Reporter activities in control human astrocytes or those overexpressing
SOD1wt or SOD1G37R cultured either alone (Basal) or with spinal cord neurons for 5 days (Neurons). (B) Western blot analysis of SOD1 expression
in the human astrocyte ALS cell models used in A. (C) The left graph shows reporter activities in olfactory mucosa cells from eight control donors
and seven ALS patients cultured either alone (Basal) or with spinal cord neurons for 1 day. Samples are ordered by ascending patient age within
each group (control and ALS). The right graph represents the combined mean and SEM of the control or ALS groups with the P-value for compari-
son of the means.
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with ALS-derived samples may trigger an inflammatory process
including activation of NF-jB pathways. Consistent with this, NF-jB
activation has previously been observed in spinal cord astrocytes in
ALS patients as well as in TDP-43 animal models where it was also
demonstrated that the inhibition of NF-jB with Withaferin A reduced
denervation in neuromuscular junctions [81, 82].
Although important advances in ALS research have been made
using mutated SOD1-expressing astrocytes, this model has the disad-
vantage that it only represents a small fraction of genetic cases of the
disease. Furthermore, transduction by the SOD1 transgene may result
in overexpression the protein at non-physiological levels or generate
other disease-unrelated artefacts such as insertional mutagenesis. In
the present study, to achieve a completely human model, we have
examined the effect of patient OM on motor neurons derived from
human foetal spinal cord. In further work, it would be interesting to
compare their effect on rodent motor neuron primary cultures, which
can be prepared cells that are more fully committed to the motor neu-
ron lineage [83, 84]. To facilitate such studies, the relative homogene-
ity of response to different ALS OM samples with respect to controls
may permit the use of pooled patient cells or perhaps even immortal-
ized cell lines to generate more user-friendly cell models for ALS. Val-
idation of OM as a cell model for ALS offers a new versatile tool to
accelerate research and therapeutic development for this presently
incurable devastating disease. Detailed characterization of OM cell
models opens up the possibility of correlating genetic and functional
differences which will facilitate the identification of more cellular com-
ponents implicated in the disease process.
Acknowledgements
We thank Carol Marchetto and Fred Gage from the Salk Institute (La Jolla, CA)
for the kind gift of the SODwt and SODG37R lentivectors. We are grateful for
advice and technical aid provided by Berta Raposo and Silvia Andrade from the
Flow Cytometry Service of the Centro de Biologıa Molecular “Severo Ochoa”.
This work was supported by grant SAF2010-22106 from the Spanish Ministry
of Science and by the agency “Pedro LaınEntralgo” for neurodegenerative dis-
eases research (2007, NDG07/6). The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manu-
script.
Conflicts of interest
The authors confirm that there are no conflicts of interest.
Supporting information
Additional Supporting Information may be found in the online
version of this article:
Figure S1 Survival of olfactory mucosa.
Figure S2 Immunocytochemistry of OM cells cultured in glial med-
ium.
References
1. Rowland LP. Amyotrophic lateral sclerosis.
Curr Opin Neurol. 1994; 7: 310–5.
2. Calvo AC, Manzano R, Mendonca DM, et al.
Amyotrophic lateral sclerosis: a focus on
disease progression. Biomed Res Int. 2014;
2014: 925101.
3. Renton AE, Chio A, Traynor BJ. State of play
in amyotrophic lateral sclerosis genetics.
Nat Neurosci. 2014; 17: 17–23.
4. Rosen DR. Mutations in Cu/Zn superoxide
dismutase gene are associated with familial
amyotrophic lateral sclerosis. Nature. 1993;
364: 362.
5. Valentine JS, Doucette PA, Zittin Potter S.
Copper-zinc superoxide dismutase and am-
yotrophic lateral sclerosis. Annu Rev Bio-
chem. 2005; 74: 563–93.
6. Sreedharan J, Blair IP, Tripathi VB, et al.
TDP-43 mutations in familial and sporadic
amyotrophic lateral sclerosis. Science. 2008;
319: 1668–72.
7. Vance C, Rogelj B, Hortobagyi T, et al.
Mutations in FUS, an RNA processing
protein, cause familial amyotrophic lateral
sclerosis type 6. Science. 2009; 323:
1208–11.
8. Kwiatkowski TJ Jr, Bosco DA, Leclerc AL,
et al. Mutations in the FUS/TLS gene on
chromosome 16 cause familial amyotrophic
lateral sclerosis. Science. 2009; 323:
1205–8.
9. Greenway MJ, Alexander MD, Ennis S,
et al. A novel candidate region for ALS on
chromosome 14q11.2. Neurology. 2004; 63:
1936–8.
10. DeJesus-Hernandez M, Mackenzie IR,
Boeve BF, et al. Expanded GGGGCC
hexanucleotide repeat in noncoding region
of C9ORF72 causes chromosome 9p-
linked FTD and ALS. Neuron. 2011; 72:
245–56.
11. Majounie E, Renton AE, Mok K, et al. Fre-
quency of the C9orf72 hexanucleotide repeat
expansion in patients with amyotrophic lat-
eral sclerosis and frontotemporal dementia:
a cross-sectional study. Lancet Neurol.
2012; 11: 323–30.
12. Renton AE, Majounie E, Waite A, et al. A
hexanucleotide repeat expansion in
C9ORF72 is the cause of chromosome
9p21-linked ALS-FTD. Neuron. 2011; 72:
257–68.
13. Boillee S, Vande Velde C, Cleveland DW.
ALS: a disease of motor neurons and their
nonneuronal neighbors. Neuron. 2006; 52:
39–59.
14. Clement AM, Nguyen MD, Roberts EA,
et al. Wild-type nonneuronal cells extend
survival of SOD1 mutant motor neurons in
ALS mice. Science. 2003; 302: 113–7.
15. Yamanaka K, Boillee S, Roberts EA, et al.
Mutant SOD1 in cell types other than motor
neurons and oligodendrocytes accelerates
onset of disease in ALS mice. Proc Natl Acad
Sci USA. 2008; 105: 7594–9.
16. Di Giorgio FP, Carrasco MA, Siao MC, et al.
Non-cell autonomous effect of glia on motor
neurons in an embryonic stem cell-based
ALS model. Nat Neurosci. 2007; 10: 608–14.
17. Nagai M, Re DB, Nagata T, et al. Astrocytes
expressing ALS-linked mutated SOD1
release factors selectively toxic to motor
neurons. Nat Neurosci. 2007; 10: 615–22.
18. Marchetto MC, Muotri AR, Mu Y, et al.
Non-cell-autonomous effect of human SOD1
G37R astrocytes on motor neurons derived
from human embryonic stem cells. Cell
Stem Cell. 2008; 3: 649–57.
ª 2015 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
1293
J. Cell. Mol. Med. Vol 19, No 6, 2015
19. Guegan C, Vila M, Rosoklija G, et al.
Recruitment of the mitochondrial-dependent
apoptotic pathway in amyotrophic lateral
sclerosis. J Neurosci. 2001; 21: 6569–76.
20. Watanabe M, Dykes-Hoberg M, Culotta VC,
et al. Histological evidence of protein aggre-
gation in mutant SOD1 transgenic mice and
in amyotrophic lateral sclerosis neural tis-
sues. Neurobiol Dis. 2001; 8: 933–41.
21. Barber SC, Shaw PJ. Oxidative stress in
ALS: key role in motor neuron injury and
therapeutic target. Free Radic Biol Med.
2010; 48: 629–41.
22. Just N, Moreau C, Lassalle P, et al. High
erythropoietin and low vascular endothelial
growth factor levels in cerebrospinal fluid
from hypoxemic ALS patients suggest an
abnormal response to hypoxia. Neuromu-
scul Disord. 2007; 17: 169–73.
23. Moreau C, Devos D, Gosset P, et al. Mech-
anisms of deregulated response to hypoxia
in sporadic amyotrophic lateral sclerosis: a
clinical study. Rev Neurol. 2010; 166: 279–
83.
24. Gagliardi S, Milani P, Sardone V, et al.
From transcriptome to noncoding RNAs:
implications in ALS mechanism. Neurol Res
Int. 2012; 2012: 278725.
25. Bilsland LG, Sahai E, Kelly G, et al. Deficits
in axonal transport precede ALS symptoms
in vivo. Proc Natl Acad Sci USA. 2010; 107:
20523–8.
26. Redler RL, Dokholyan NV. The complex
molecular biology of amyotrophic lateral
sclerosis (ALS). Prog Mol Biol Transl Sci.
2012; 107: 215–62.
27. McGeer PL, McGeer EG. Inflammatory pro-
cesses in amyotrophic lateral sclerosis.
Muscle Nerve. 2002; 26: 459–70.
28. Schiffer D, Cordera S, Cavalla P, et al.
Reactive astrogliosis of the spinal cord in
amyotrophic lateral sclerosis. J Neurol Sci.
1996; 139: 27–33.
29. Anneser JM, Chahli C, Ince PG, et al. Glial
proliferation and metabotropic glutamate
receptor expression in amyotrophic lateral
sclerosis. J Neuropathol Exp Neurol. 2004;
63: 831–40.
30. Casula M, Iyer AM, Spliet WG, et al. Toll-
like receptor signaling in amyotrophic lateral
sclerosis spinal cord tissue. Neuroscience.
2011; 179: 233–43.
31. Wang R, Yang B, Zhang D. Activation of
interferon signaling pathways in spinal cord
astrocytes from an ALS mouse model. Glia.
2011; 59: 946–58.
32. Baron P, Bussini S, Cardin V, et al. Produc-
tion of monocyte chemoattractant protein-1
in amyotrophic lateral sclerosis. Muscle
Nerve. 2005; 32: 541–4.
33. Tateishi T, Yamasaki R, Tanaka M, et al.
CSF chemokine alterations related to the
clinical course of amyotrophic lateral sclero-
sis. J Neuroimmunol. 2010; 222: 76–81.
34. Poloni M, Facchetti D, Mai R, et al. Circu-
lating levels of tumour necrosis factor-alpha
and its soluble receptors are increased in
the blood of patients with amyotrophic
lateral sclerosis. Neurosci Lett. 2000; 287:
211–4.
35. Keller AF, Gravel M, Kriz J. Live imaging of
amyotrophic lateral sclerosis pathogenesis:
disease onset is characterized by marked
induction of GFAP in Schwann cells. Glia.
2009; 57: 1130–42.
36. Ferraiuolo L, Heath PR, Holden H, et al.
Microarray analysis of the cellular pathways
involved in the adaptation to and progres-
sion of motor neuron injury in the SOD1
G93A mouse model of familial ALS. J Neuro-
sci. 2007; 27: 9201–19.
37. Letiembre M, Liu Y, Walter S, et al.
Screening of innate immune receptors in
neurodegenerative diseases: a similar pat-
tern. Neurobiol Aging. 2009; 30: 759–68.
38. Liu Y, Hao W, Dawson A, et al. Expression
of amyotrophic lateral sclerosis-linked SOD1
mutant increases the neurotoxic potential of
microglia via TLR2. J Biol Chem. 2009; 284:
3691–9.
39. Zhao W, Beers DR, Henkel JS, et al. Extra-
cellular mutant SOD1 induces microglial-
mediated motoneuron injury. Glia. 2010; 58:
231–43.
40. Knippenberg S, Sipos J, Thau-Habermann
N, et al. Altered expression of DJ-1 and
PINK1 in sporadic ALS and in the
SOD1G93A ALS mouse model. J Neuropa-
thol Exp Neurol. 2013; 72: 1052–61.
41. Haidet-Phillips AM, Hester ME, Miranda
CJ, et al. Astrocytes from familial and spo-
radic ALS patients are toxic to motor neu-
rons. Nat Biotechnol. 2011; 29: 824–8.
42. Burkhardt MF, Martinez FJ, Wright S, et al.
A cellular model for sporadic ALS using
patient-derived induced pluripotent stem
cells. Mol Cell Neurosci. 2013; 56: 355–64.
43. de Munck E, Munoz-Saez E, Miguel BG,
et al. beta-N-methylamino-l-alanine causes
neurological and pathological phenotypes
mimicking Amyotrophic Lateral Sclerosis
(ALS): the first step towards an experimental
model for sporadic ALS. Environ Toxicol
Pharmacol. 2013; 36: 243–55.
44. Feron F, Perry C, McGrath JJ, et al. New
techniques for biopsy and culture of human
olfactory epithelial neurons. Arch Otolaryn-
gol Head Neck Surg. 1998; 124: 861–6.
45. Ronnett GV, Leopold D, Cai X, et al. Olfac-
tory biopsies demonstrate a defect in neuro-
nal development in Rett’s syndrome. Ann
Neurol. 2003; 54: 206–18.
46. Wolozin B, Zheng B, Loren D, et al. Beta/A4
domain of APP: antigenic differences
between cell lines. J Neurosci Res. 1992; 33:
189–95.
47. Abrams MT, Kaufmann WE, Rousseau F,
et al. FMR1 gene expression in olfactory
neuroblasts from two males with fragile X
syndrome. Am J Med Genet. 1999; 82: 25–
30.
48. Feron F, Perry C, Hirning MH, et al. Altered
adhesion, proliferation and death in neural
cultures from adults with schizophrenia.
Schizophr Res. 1999; 40: 211–8.
49. Arnold SE, Han LY, Moberg PJ, et al. Dys-
regulation of olfactory receptor neuron line-
age in schizophrenia. Arch Gen Psychiatry.
2001; 58: 829–35.
50. McCurdy RD, Feron F, Perry C, et al. Cell
cycle alterations in biopsied olfactory neu-
roepithelium in schizophrenia and bipolar I
disorder using cell culture and gene expres-
sion analyses. Schizophr Res. 2006; 82:
163–73.
51. Roisen FJ, Klueber KM, Lu CL, et al. Adult
human olfactory stem cells. Brain Res.
2001; 890: 11–22.
52. Murrell W, Feron F, Wetzig A, et al. Multi-
potent stem cells from adult olfactory
mucosa. Dev Dyn. 2005; 233: 496–515.
53. Murrell W, Sanford E, Anderberg L, et al.
Olfactory stem cells can be induced to
express chondrogenic phenotype in a rat
intervertebral disc injury model. Spine J.
2009; 9: 585–94.
54. Murrell W, Wetzig A, Donnellan M, et al.
Olfactory mucosa is a potential source for
autologous stem cell therapy for Parkinson’s
disease. Stem Cells. 2008; 26: 2183–92.
55. Au E, Roskams AJ. Olfactory ensheathing
cells of the lamina propria in vivo and in vi-
tro. Glia. 2003; 41: 224–36.
56. Doucette JR. The glial cells in the nerve fiber
layer of the rat olfactory bulb. Anat Rec.
1984; 210: 385–91.
57. Feron F, Perry C, Cochrane J, et al. Autolo-
gous olfactory ensheathing cell transplanta-
tion in human spinal cord injury. Brain.
2005; 128: 2951–60.
58. Lu J, Feron F, Ho SM, et al. Transplantation
of nasal olfactory tissue promotes partial
recovery in paraplegic adult rats. Brain Res.
2001; 889: 344–57.
59. Morita E, Watanabe Y, Ishimoto M, et al. A
novel cell transplantation protocol and its
application to an ALS mouse model. Exp
Neurol. 2008; 213: 431–8.
60. Li Y, Bao J, Khatibi NH, et al. Olfactory en-
sheathing cell transplantation into spinal
1294 ª 2015 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
cord prolongs the survival of mutant SOD1
(G93A) ALS rats through neuroprotection
and remyelination. Anat Rec. 2011; 294:
847–57.
61. Chen L, Chen D, Xi H, et al. Olfactory en-
sheathing cell neurorestorotherapy for am-
yotrophic lateral sclerosis patients: benefits
from multiple transplantations. Cell Trans-
plant. 2012; 21: S65–77.
62. Huang ZH, Wang Y, Cao L, et al. Migratory
properties of cultured olfactory ensheathing
cells by single-cell migration assay. Cell
Res. 2008; 18: 479–90.
63. Vincent AJ, Choi-Lundberg DL, Harris JA,
et al. Bacteria and PAMPs activate nuclear
factor kappaB and Gro production in a sub-
set of olfactory ensheathing cells and astro-
cytes but not in Schwann cells. Glia. 2007;
55: 905–16.
64. Vincent AJ, Taylor JM, Choi-Lundberg DL,
et al. Genetic expression profile of olfactory
ensheathing cells is distinct from that of
Schwann cells and astrocytes. Glia. 2005;
51: 132–47.
65. €Ozdener MH, Rawson NE. Olfactory dys-
function in neurodegenerative diseases. Eur
J Gen Med. 2004; 1: 1–11.
66. Doty RL. Studies of olfactory dysfunction in
major neurological disorders. Adv Biosci.
1994; 93: 593–602.
67. Ahlskog JE, Waring SC, Petersen RC, et al.
Olfactory dysfunction in Guamanian ALS,
parkinsonism, and dementia. Neurology.
1998; 51: 1672–7.
68. Federico G, Maremmani C, Cinquanta L,
et al. Mucus of the human olfactory epithe-
lium contains the insulin-like growth factor-I
system which is altered in some neurode-
generative diseases. Brain Res. 1999; 835:
306–14.
69. Matigian N, Abrahamsen G, Sutharsan R,
et al. Disease-specific, neurosphere-derived
cells as models for brain disorders. Dis
Model Mech. 2010; 3: 785–98.
70. Abrahamsen G, Fan Y, Matigian N, et al. A
patient-derived stem cell model of hereditary
spastic paraplegia with SPAST mutations.
Dis Model Mech. 2013; 6: 489–502.
71. Sanchez Martin C, Diaz-Nido J, Avila J.
Regulation of a site-specific phosphorylation
of the microtubule-associated protein 2 dur-
ing the development of cultured neurons.
Neuroscience. 1998; 87: 861–70.
72. Garcia-Escudero V, Garcia-Gomez A, Langa
E, et al. Patient-derived olfactory mucosa
cells but not lung or skin fibroblasts mediate
axonal regeneration of retinal ganglion neu-
rons. Neurosci Lett. 2012; 509: 27–32.
73. Cardesin A, Alobid I, Benitez P, et al. Bar-
celona Smell Test - 24 (BAST-24): validation
and smell characteristics in the healthy
Spanish population. Rhinology. 2006; 44:
83–9.
74. Garaulet G, Alfranca A, Torrente M, et al.
IL10 released by a new inflammation-regu-
lated lentiviral system efficiently attenuates
zymosan-induced arthritis. Mol Ther. 2013;
21: 119–30.
75. Garcia-Escudero V, Garcia-Gomez A, Gar-
gini R, et al. Prevention of senescence pro-
gression in reversibly immortalized human
ensheathing glia permits their survival after
deimmortalization. Mol Ther. 2010; 18: 394–
403.
76. Koechling T, Khalique H, Sundstrom E,
et al. A culture model for neurite regenera-
tion of human spinal cord neurons. J Neuro-
sci Methods. 2011; 201: 346–54.
77. Zhao W, Beers DR, Appel SH. Immune-
mediated mechanisms in the pathoprogres-
sion of amyotrophic lateral sclerosis. J Neu-
roimmune Pharmacol. 2013; 8: 888–99.
78. Phani S, Re DB, Przedborski S. The role of
the innate immune system in ALS. Front
Pharmacol. 2012; 3: 150.
79. Bosco DA, Morfini G, Karabacak NM, et al.
Wild-type and mutant SOD1 share an aber-
rant conformation and a common patho-
genic pathway in ALS. Nat Neurosci. 2010;
13: 1396–403.
80. Henkel JS, Beers DR, Zhao W, et al. Micro-
glia in ALS: the good, the bad, and the rest-
ing. J Neuroimmune Pharmacol. 2009; 4:
389–98.
81. Migheli A, Piva R, Atzori C, et al. c-Jun,
JNK/SAPK kinases and transcription factor
NF-kappa B are selectively activated in astro-
cytes, but not motor neurons, in amyotroph-
ic lateral sclerosis. J Neuropathol Exp
Neurol. 1997; 56: 1314–22.
82. Swarup V, Phaneuf D, Dupre N, et al.
Deregulation of TDP-43 in amyotrophic lat-
eral sclerosis triggers nuclear factor kappaB-
mediated pathogenic pathways. J Exp Med.
2011; 208: 2429–47.
83. Anderson KN, Potter AC, Piccenna LG,
et al. Isolation and culture of motor neu-
rons from the newborn mouse spinal cord.
Brain Res Brain Res Protoc. 2004; 12:
132–6.
84. Cheng S, Shi Y, Hai B, et al. Culture of
motor neurons from newborn rat spinal
cord. J Huazhong Univ Sci Technolog Med
Sci. 2009; 29: 413–6.
ª 2015 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
1295
J. Cell. Mol. Med. Vol 19, No 6, 2015
